Core Insights - BioHarvest Sciences Inc. has been invited to present at the Canaccord Genuity 45th Annual Growth Conference scheduled for August 12-14, 2025, in Boston, Massachusetts [1] - CEO Ilan Sobel will conduct one-on-one meetings with institutional investors and will present the company's growth plans during the conference [2][3] - The company is focused on building momentum in both its consumer and contract development and manufacturing organization (CDMO) businesses, aiming to scale operations effectively [3] Company Overview - BioHarvest Sciences Inc. specializes in Botanical Synthesis, utilizing its patented technology to produce plant-based compounds without the need for growing the actual plants [4] - The company operates in two main business verticals: as a CDMO for clients seeking novel plant-based compounds and as a creator of proprietary nutraceutical health and wellness products, including dietary supplements [4]

Core Viewpoint - BioHarvest Sciences Inc. has launched VINIA® DailyChews 2X Formula, a chewable product designed to enhance nitric oxide production and improve blood flow for athletes and active individuals, now available for purchase online [1][3]. Product Details - VINIA® DailyChews 2X Formula contains 800mg of VINIA® and 12mg of Piceid resveratrol, which is clinically shown to increase arterial dilation, thereby improving physical energy and mental alertness [3]. - The product is Informed Sport-certified, ensuring that every batch is tested for banned substances, making it suitable for professional athletes and fitness enthusiasts [2][3]. Market Strategy - The launch targets the multi-billion-dollar nutraceuticals market, aiming to attract a younger consumer base and expand into the athlete and fitness enthusiast segment [3]. - BioHarvest is enhancing its international e-commerce platform to facilitate global orders, allowing customers in countries like the UK and Australia to receive products directly [3]. Company Background - BioHarvest Sciences Inc. specializes in Botanical Synthesis technology, enabling the growth of plant-based compounds without the need for the actual plants [8]. - The company operates in two major business verticals: as a contract development and manufacturing organization (CDMO) and as a creator of proprietary nutraceutical health and wellness products [8].

Core Insights - BioHarvest Sciences Inc. has secured a new contract for developing a plant-based fragrance compound, targeting the multi-billion-dollar fragrance and scents market [1][3] - The contract will utilize the company's proprietary Botanical Synthesis technology and advanced AI-assisted research capabilities to identify specific plant species for efficient production [2][4] - The agreement includes milestone-based payments and a non-disclosure agreement for the initial stage of the project [3] Company Overview - BioHarvest is a leader in Botanical Synthesis, leveraging patented technology to grow plant-based compounds without the need for the actual plants [5] - The company operates in two major business verticals: as a contract development and manufacturing organization (CDMO) and as a creator of proprietary nutraceutical health and wellness products [5][6] - The CEO emphasized the contract's potential to expand the company's reach into the high-value fragrance space while contributing to the conservation of threatened plant species [4]

Core Insights - BioHarvest Sciences reported a 47% increase in first-quarter revenues, reaching $7.9 million, surpassing management's guidance [3][8][11] - The growth was primarily driven by the VINIA® business, which achieved over 50,000 active subscribers by February 2025 [3][5] - The company is expanding its product offerings and marketing strategies to target younger consumer segments [4][7] Financial Performance - Total revenues for Q1 2025 increased to $7.9 million from $5.3 million in Q1 2024, marking a 47% year-over-year growth [8] - Gross profit rose by 53% to $4.6 million, with gross margins improving to 58.5% from 56.2% [9][22] - Operating expenses increased to $6.3 million, primarily due to higher marketing expenditures, but as a percentage of revenue, it decreased to 46.8% from 48.0% [10][22] Loss and Financing - The net loss for Q1 2025 was $2.3 million, a significant reduction from a net loss of $6.6 million in the same quarter of the previous year [11][22] - The company raised $3.9 million in debt financing during the quarter, increasing cash and cash equivalents to $3.4 million [12][24] Operational Highlights - The company is advancing its CDMO division, with successful validation of its botanical synthesis platform for various molecule types [5][6] - New product lines under the VINIA® brand are being introduced, including VINIA® SuperFood Tea and VINIA® Espresso, aimed at capturing a younger demographic [4][7] - The company anticipates continued growth in both its product and service units, with expectations of reaching adjusted EBITDA breakeven in the second half of 2025 [5][7]